$RLFTF (related) copy by frenchman yhoobrd - Many of us

New Post Public Reply Private Reply Replies (1) Message Board
mc67
384
$RLFTF (related) copy by frenchman yhoobrd - Many of us here have been lambasting the FDA for their delay tactics- word is starting to spread:

“FDA regulators are wasting precious time in greenlighting a COVID vaccine as more than 2,000 Americans are dying each day and the pandemic continues to starve American society.

Pfizer submitted data detailing the safety and effectiveness of its vaccine on Nov. 22. But rather than immediately convening experts, the FDA scheduled a review meeting on Dec. 10, almost three weeks later. As Pfizer’s application sits on the shelf at the FDA awaiting authorization, about 27,000 Americans will have died. So what is the FDA doing for three weeks?

As a Johns Hopkins scientist who has conducted more than 100 clinical studies and reviewed thousands more from the scientific community at large, I can assure you that the agency’s review can be done within 24 to 48 hours without cutting any corners. They just need to work harder.

Contrary to popular belief, the FDA process is not hands-on—it does not interview vaccine trial patients or look under a microscope at the immune cells. It’s doing a statistical analysis and looking at data. For the vaccine trial, the data set is small and straightforward. If my research team, normally tasked with analyzing data on millions of patients, was asked to review the smaller Pfizer vaccine study of 43,000 patients, it would take about one hour.

The FDA also reviews manufacturing data from Pfizer on how they made the drug. But not only can that data be reviewed in a few hours, it should have been done months ago when it was available. While the FDA was waiting for Pfizer’s long-term vaccine results to come in, the agency should have anticipated this step and done it early.

The final step of the FDA review is to look at the outcomes of the study volunteers, including rates and severity of infection and side effects in the vaccine and placebo groups. Again, there is no plausible reason why this basic analysis cannot be done in 24 hours. The FDA and external scientists have a simple task: confirm or reject the review already conducted by the trial’s independent data safety monitoring board before FDA submission.

Let me be clear: The agency should not cut any corners in its review process, just cut out the sitting-around time. FDA insiders say the agency and its approximately 17,000 employees were dark for the four-day Thanksgiving holiday, including those working on the vaccine approval. It’s time the FDA adopts a sense of urgency. We’ve had Operation Warp Speed in developing vaccines but Operation Turtle Speed in reviewing the results...”

https://thedispatch.com/p/fda-career-staff-are-delaying-the

- some replies -

Zaran
thank you, sorry state we are in


m
@Bridge for future reference I would just have someone focus on the most efficacious of the two which is RLF-100, right? I don’t known if leronlimab is putting out numbers that are overall better than Aviptadil.


Bridge
I tweeted to Dr. Makary, responding to an earlier tweet of his. I know it’s probably useless, and after all what could he do? But I find myself sending out a tweet every few days to someone who may be able to raise these concerns. Maybe better than just watching this nightmarish delay, which makes so little sense.

Read your article re FDA vaccine delay. Same with COVID TREATMENTS like #Leronlimab and #Aviptadil
- In trials since April/May
- MOA against COVID is known
- Qualify for EUA: are SAFE and without doubt “may be” effective
- FDA is taking so long while so many die
- Can you help?


m
Dr. Marty should have focused on RLF-100 and it’s slow progress because it has a known safety profile whereas vaccines are not as well known. Pushing out RLF-100 in the 10’s of millions this December would have done more than the vaccines will. I could be wrong but would love to learn why.


Bridge
Thanks for posting. What an indictment! And that’s just the vaccines. We all knew it didn’t make sense that viable treatments like RLF-100 and leronlimab are still sitting on the shelf.

What the hell is going on? I don’t think it can be corruption like big pharma money. No half-way normal person would allow tens of thousands of deaths for money. It must be some combination of things like human complacency and stupidity. It’s hard to witness this nightmare.


crymeariver
They should focus on saving dying people instead of vaccinating healthy people.


frenchman
@BigGator There doesn’t seem to be a sense of urgency - the question is why?

Mondobiotech Holding AG Basel (RLFTF) Stock Research Links

RLFTF Board Company Profile Buy Rating Time & Sales News Filings Financials
$MJ
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Choice Hotels Hits Milestones and Faces Market Scrutiny

Updated Category News Views 282

Another Quarter Under the Belt Just when you think the hospitality industry's running out of steam, Choice Hotels International decides to shake things up. Reporting their third quarter 2026 results, the big picture here demands an attentive eye from investors. In the turbulent world of lodging franchises, NYSE:CHH is making waves, and I mean literal waves, as they surf...

Continue Reading
ADC Therapeutics Preps Financial Results Release

Updated Category News Views 66

ADC Therapeutics: Eyes on the Financial Prize So here we are, folks—ADC Therapeutics is blitzing the stage and gearing up to spill the beans on their third-quarter saga come November 9, 2026. Who needs a crystal ball when you've got a press release to dissect every number and nuance? Anticipating the Numbers: What's at Stake? ADC Therapeutics has been riding the wave of...

Continue Reading
YR Fitness Rolls Out Innovator's Iron at FIBO 2027

Updated Category News Views 23

A New Era of Strength Training Equipment? That's the question I asked myself when I heard about YR Fitness showcasing their latest gym gear at FIBO 2027. This isn't just another batch of machines rolling off the production line. YR Fitness has become quite the icon in China for strength equipment, and they're dead set on shaking up the market in Cologne, Germany from...

Continue Reading
Gamehaus Expands with Anamana AI-Driven Acquisition

Updated Category News Views 119

Gamehaus Moves Deep Into AI Waters Sailing right into a new frontier, Gamehaus is all set to splash $19.6 million for a hefty slice of Techforge, the parent of the AI-powered Anamana. Gamehaus: a game publisher taking aim at becoming an AI content giant. You might ask yourself, "Can they pull it off?" Well, that's what I'm pondering over my lukewarm coffee today....

Continue Reading
Pak Mail Jonesboro Dominates at Annex Brands Convention

Updated Category News Views 44

Small Town, Big Impact at the Annex Brands Shindig From little Jonesboro, Arkansas, comes a thunderous clap for the Kincades, who bagged a bunch of trophies and accolades at the big 2026 Annex Brands National Convention. Tim and Rhonda Kincade, the ones running Pak Mail Jonesboro, didn't just show up—they brought home the bacon with honors piled as high as the Ozarks....

Continue Reading
Texas A&M, Natura Tackle Nuclear Waste Recycling

Updated Category News Views 96

Ambitious Nuclear Fuel Recycling Underway Talk about turning trash into treasure. Natura Resources has teamed up with Texas A&M in a bold project aiming to recycle nuclear waste into usable fuel for new reactors. They've got federal backing to the tune of $5.4 million, courtesy of the U.S. Department of Energy. This effort to harness old nuclear waste has the potential to...

Continue Reading
Aosom Unveils Its Boldest Black Friday Extravaganza

Updated Category News Views 67

Black Friday Heat Kicks Off Early at Aosom All the seasoned shoppers out there smell a deal from a mile away, and Aosom isn't taking any chances by launching their Black Friday bash smack dab on November 2nd. This isn’t just any sale, it’s shaping up to be their most gigantic festival of discounts yet. Across Europe and North America, folks are rubbing their hands...

Continue Reading
Winter Roof Woes: How to Handle Ice and Snow Load

Updated Category News Views 64

Understanding Roof Load Limits You don't have to be in the roofing business to know that Central NY doesn't mess around when winter hits. Michael Majeski, a name trusted in Watertown, NY, is sounding the alarm on how snow and ice can either shake a roof or break it. Talking about roof 'load limits' might sound all fancy, but in plain talk, it's about knowing when your...

Continue Reading
EASE Unlocks $9.5M for AI Medical Expansion in Africa

Updated Category News Views 141

Transforming Healthcare in South Africa and Ghana Expanding into uncharted territories often requires a leap of faith, and EASE Holdings has just taken a substantial one. The medical equipment-as-a-service provider has grabbed a hefty $9.5 million in equity from AAFC Group Inc. The goal? To flood South Africa and Ghana with cutting-edge medical imaging and surgical...

Continue Reading
FirstEnergy's Timely Transformer Boosts Lakewood Power

Updated Category News Views 149

Lakewood's Power Strengthened Ahead of Schedule Nothing like beating your own deadlines to put a spring in your step, huh? FirstEnergy (NYSE:FE) has pulled off just that by energizing a second big ol’ transformer in Lakewood ahead of time. Feels like a solid win under their belts, especially in a world where delays seem to be the norm. Now, this isn't just any swap-out...

Continue Reading

Top 5 Most Recently Viewed Articles

Youth Vulnerability In the Face of Quickening Nicotine Trends

Updated Category News Views 215

Urgent Need for Action Against Evolving Nicotine Market Recent reports reveal alarming trends in the nicotine market, highlighting how rapidly evolving products are taking precedence over regulatory efforts, potentially jeopardizing youth health. With innovative nicotine delivery systems hitting the market, including high-tech vapes, flavored pouches, and disposable...

Continue Reading
Societe Generale Announces Leadership Changes to Foster Growth

Updated Category News Views 133

Significant Managerial Changes at Societe Generale Societe Generale is making noteworthy managerial changes intended to foster growth and improve operational efficiency within the Group. These alterations reflect the organization's commitment to adapting to the ever-evolving banking landscape and enhancing the focus on its diverse operations. Leadership Structure...

Continue Reading
Blue Owl Capital Corp Sees Robust Earnings and Growth

Updated Category News Views 68

Financial Highlights from Blue Owl Capital Corporation Blue Owl Capital Corporation (NYSE: OBDC) has released its financial performance metrics for the recent quarter. The report reveals a net investment income per share of $0.47, illustrating a solid performance amid varying market conditions. This figure surpasses the aforementioned regular dividend of $0.37 by 27%,...

Continue Reading
Neuronetics Plans Engaging Presentation at Key Healthcare Event

Updated Category News Views 172

Neuronetics set to present at an important healthcare conference Neuronetics, Inc. (NASDAQ: STIM), a pioneering company dedicated to developing advanced medical technologies, has announced its participation in a significant healthcare conference. The event is the Piper Sandler 36th Annual Healthcare Conference, where Neuronetics' management team will deliver a...

Continue Reading
Automated Guided Vehicles Market Soars to USD 12.7 Billion by 2034

Updated Category News Views 113

Understanding Automated Guided Vehicles and Their Market Growth Automated Guided Vehicles (AGVs) are revolutionizing how materials are moved within various industries. As more companies adopt automation, the AGV market is anticipated to grow significantly in the coming years. A recent study projects that the market was valued at approximately USD 5.4 billion and is...

Continue Reading